Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InSite Vision has reported the start of a phase I study to examine the safety and tolerability of AzaSite Plus, a combination of antibiotic and corticosteroid.
Subscribe to our email newsletter
AzaSite Plus, the next product in the AzaSite product franchise, combines azithromycin and dexamethasone in DuraSite which is InSite Vision's drug delivery system for topical ophthalmic indications.
The product would be indicated for ocular treatment where inflammation and bacterial infection are present, typically represented in conditions such as blepharitis.
InSite Vision commented that AzaSite Plus provides broad bacteria coverage, featuring reduced dosing and drug safety, while the addition of dexamethasone provides a proven steroid for the treatment of ocular inflammation.
“We expect this product to expand the overall market for our AzaSite franchise to other significant indications, based on the demonstrated efficacy and convenience of our AzaSite product,” stated Kumar Chandrasekaran, president and CEO of InSite Vision.